ALGOTHERAPEUTIX
15.12.2020 08:17:14 CET | Business Wire | Press release
France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), announced today it has received approval from the ethics committee and the regulatory authority in the Czech Republic to initiate a Phase 1 clinical trial with ATX01. The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021.
AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. Given a positive outcome of the approved Phase 1 study, the company intends to initiate Phase 2 by the end of 2021.
Stéphane Thiroloix , Founder & CEO of AlgoTherapeutix, says: “I am thrilled by the entry of ATX01 in clinical development as it represents a great step forward towards providing CIPN patients with a response to the crippling pain they endure.”
Over half of cancer patients treated with chemotherapy - over two million patients in the US and Europe - develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN is a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.
Over the last two years, AlgoTherapeutix took ATX01 from exploratory prototype to final formulation, established its pharmacological profile, conducted a full pre-clinical toxicology package, and scaled-up manufacturing to enable clinical supply production. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.
A recent publication in the “Journal of Pain” describes the exploratory pharmacological impact of high-dose topical amitriptyline in CIPN patients along with the mechanism of action supporting its activity (https://doi.org/10.1016/j.jpain.2020.11.002 )
About AlgoTherapeutix
AlgoTx was founded in 2018 by Stéphane Thiroloix and Olivier Bohuon to develop topical treatments for complex pain and was incubated by Paris Biotech Santé. Their lead programme ATX01 is in clinical development in Chemotherapy-Induced Peripheral Neuropathy. More information at www.algotx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Signaloid Announces Appointment of Quantitative Finance and Cloud Veterans to Advisory Board and Senior Commercialization Roles14.9.2026 05:00:00 CEST | Press release
Signaloid strengthens commercialization momentum with the appointment of two senior advisors in quantitative finance and cloud infrastructure.Dr. Han Lee, former Global Head of Quantitative Strategies and Automated Trading at Morgan Stanley, joins to chair Signaloid’s advisory board.Dr. Nachiketh Potlapally, Distinguished Engineer at Nscale, and previously Security Architect at Oracle Cloud Infrastructure and AWS, joins as Signaloid expands deployment of its UxHw technology across cloud and edge environments.Christian Roth, former Senior Director Enterprise Sales / formerly Director Product Marketing EMEA (Data Center, Business Clients, Storage and Networking), Intel. British technology company Signaloid today announced the appointment of three distinguished industry veterans to its advisory board and senior leadership roles, to strengthen the commercialization momentum behind its technology: Dr. Han Lee, former Global Head of Quantitative Strategies and Automated Trading for the Fixed
SES’s Final Three O3b mPOWER Satellites Successfully Launched13.9.2026 22:22:00 CEST | Press release
Additional O3b mPOWER satellites complete constellation and strengthen performance, resiliency and reach of SES's MEO network SES today announced the successful launch of its eleventh, twelfth and thirteenth O3b mPOWER satellites, further expanding its second-generation medium Earth orbit (MEO) system designed to offer high-performance connectivity services around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260913914517/en/ SES’s Final Three O3b mPOWER Satellites Successfully Launched The three satellites launched at 2:49 pm local time aboard a SpaceX Falcon 9 rocket from Space Launch Complex 40 (SLC-40) at Cape Canaveral Space Force Station. “This launch marks a defining milestone for SES as we complete the O3b mPOWER constellation and further strengthen our MEO capabilities,” said Adel Al-Saleh, CEO of SES. “More importantly, it reinforces our ability to deliver resilient, secure and scalable connectivity for
Aster Guardians Global Nursing Award 2026 Names Agimol Pradeep From United Kingdom Winner of USD 250,000 Prize12.9.2026 21:27:00 CEST | Press release
From more than 134,000 registrations spanning 214 countries and economies, Nurse Agimol Pradeep from United Kingdom has been announced as the winner of the Aster Guardians Global Nursing Award 2026. A Senior Transplant Coordinator at King’s College Hospital and Honorary Senior Lecturer at the University of Salford, UK, she was recognised with USD 250,000 at a prestigious ceremony held in Kochi, India. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260912257725/en/ Nurse Agimol Pradeep - Aster Guardians Global Nursing Award 2026 Winner (Photo: AETOSWire) Since its launch in 2021, the Aster Guardians Global Nursing Award has grown into a global platform that celebrates nurses who are advancing the profession and creating meaningful change. The award was presented by Shri V. D. Satheesan, Hon’ble Chief Minister of Keralam, in presence of Dr. Azad Moopen and Alisha Moopen. The ceremony also featured a special message from Dr. Te
Last Night, a Star-studded Evening Celebrating Moncler’s Fifth Avenue Flagship Ushered in a New Chapter in the Brand’s Enduring Love Story With New York11.9.2026 23:01:00 CEST | Press release
Last night, on occasion of the opening of Moncler’s largest-ever global flagship on Fifth Avenue, special guests including Cher, Julia Roberts, Anne Hathaway, Serena Williams, Future, Spike Lee, Jessica Chastain, Adrien Brody, Odell Beckham Jr., Maria Sharapova, Colin Kaepernick, Adriana Lima, Mark Ronson, Shaun White, Helena Christensen, Penn Badgley, Gus Kenworthy, Jordan Clarkson, Coco Rocha, François Arnaud, Gavin Casalegno, Jacob Whiteduck-Lavoie, Sam Nivola, Evan Mock, Sammi Cheng, Princess Olympia of Greece, Hiroshi Fujiwara, Daniel Arsham, Edward Enninful, Tobe and Fat Nwigwe, Joaquín Furriel, Lucas Pinheiro Braathen, Nic von Rupp, Daniel Humm, Juliana Awad, Mickalene Thomas, Questlove, Michael Rainey Jr., Pete Davidson, and Francis Mallmann came together to mark a new chapter in the brand’s decades-long relationship with New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260904757149/en/ MONCLER FIFTH AVE
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research11.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent international pharmaceutical group governed by a foundation, to license K Pro, Owkin’s AI Scientist, together with multimodal patient data to advance the company’s oncology research. Under the agreement, Owkin will make multimodal patient data from its MOSAIC network accessible for analysis to Servier’s research teams, within K Pro. This agreement is the next chapter in Owkin and Servier’s collaboration, their previous work together being in patient subgroup identification, also in oncology. K Pro is Owkin’s AI scientist. It brings multimodal patient data and specialized biological agentic AI to drive smarter and faster decision-making to each step of the pharmaceutical value chain. K Pro utilizes specialized biological tools, leveraging a decade of knowledge gained through pharmaceutical partnerships and st
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom